P1.01-025 Biomarker Testing in Advanced NSCLC: A Simulation-Based Assessment of Medical Oncologists
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2017.09.679
Abstract: standards of care for patients with advanced non-small cell lung cancer (NSCLC), which has resulted in 5 updates to the National Comprehensive Cancer Network (NCCN) Lung Cancer Guidelines® in 2017 alone.1 As a result, oncologists… read more here.
Keywords: 025 biomarker; biomarker testing; advanced nsclc; simulation ... See more keywords
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.11.038
Abstract: INTRODUCTION A prospective investigation of the circulating immune profile in NSCLC patients receiving nivolumab was performed to identify potentially predictive parameters. METHODS Flow Cytometry of peripheral blood (PB) CD3+, CD8+, CD4+, NK, Treg and MDSCs… read more here.
Keywords: anti pd1; pd1 treatment; cd8; cd8 cells ... See more keywords
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.2023213
Abstract: Abstract Background Immune checkpoint inhibitors (ICIs) are implemented as standard treatment for patients with advanced non-small cell lung cancer (NSCLC) in first-line and subsequent-line treatment. However, certain subgroups such as patients with older age, poor… read more here.
Keywords: patients advanced; immune checkpoint; treatment; clinical features ... See more keywords
The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2017.1294157
Abstract: ABSTRACT Introduction: Immune checkpoint inhibition is a novel treatment modality that has brought a new hope to patients with advanced NSCLC. Several molecules targeting cytotoxic T-lymphocyte antigen 4 (CTLA4) or programmed cell death 1 receptor/programmed… read more here.
Keywords: immune checkpoint; checkpoint inhibitors; advanced nsclc; role ... See more keywords
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2026772
Abstract: ABSTRACT Introduction Chemo-immunotherapy combinations have revolutionized our treatment algorithm with respect to naïve advanced NSCLC; however, given the great number of developed and approved combinations, the question arises as to which combinations provide the best… read more here.
Keywords: chemo immunotherapy; chemotherapy; immunotherapy combinations; treatment ... See more keywords
Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz269.013
Abstract: Abstract Background Next generation sequencing (NGS) of cfDNA in NSCLC is entering in clinical practice. Several commercially available platforms using NGS report wide variety of somatic aberrations. Vendors also include therapeutic suggestions to guide oncologists.… read more here.
Keywords: advanced nsclc; escat oncokb; vaf; application escat ... See more keywords
Predictive value of microvascular density for response to anlotinib in advanced NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028647
Abstract: Supplemental Digital Content is available in the text Abstract Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer. This study aimed to categorize the microvessels in advanced NSCLC and determine the… read more here.
Keywords: density; microvascular density; response anlotinib; advanced nsclc ... See more keywords
Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct113
Abstract: Background : The anti-PD-L1 antibody durvalumab (D) has shown manageable safety and encouraging clinical activity in patients with advanced NSCLC. Combination of D with anti-CTLA-4 antibody tremelimumab (T) may amplify T-cell responses against tumors through… read more here.
Keywords: tremelimumab; non squamous; safety; advanced nsclc ... See more keywords
Abstract 6098: Gut microbiome predicts response to immunotherapy in advanced NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-6098
Abstract: Introduction: It has demonstrated that gut microbiome could affect the response to anti-programmed death 1 (PD-1) immunotherapy in the Western population. And one study has suggested that the diversity of gut microbiome was associated with… read more here.
Keywords: advanced nsclc; immunotherapy; response; gut microbiome ... See more keywords
Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221138386
Abstract: Background: A significant proportion of patients with non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with increased glycolysis is a hallmark of cancer and is involved in immune… read more here.
Keywords: advanced nsclc; immune checkpoint; fdg pet; 18f fdg ... See more keywords
Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies
Sign Up to like & getrecommendations! Published in 2020 at "BMC Cancer"
DOI: 10.1186/s12885-020-07527-4
Abstract: Background Both intermittent intravenous (IIV) infusion and continuous intravenous (CIV) infusion of Endostar are widely used for NSCLC in China. We aimed to compare the efficacy and safety of CIV of Endostar versus IIV in… read more here.
Keywords: infusion; advanced nsclc; intermittent intravenous; civ endostar ... See more keywords